Exclusive: Prison and multibillion dollar buyouts later, Sam Waksal is all in on the biotech game, with some big-name backers

Amber Tong

Sam Waksal isn’t letting a five-year prison stretch for one of the most infamous insider trading scandals in Wall Street history stop him from doing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Exclusive: Prison and multibillion dollar buyouts later, Sam Waksal is all in on the biotech game, with some big-name backers

Amber Tong

Sign up to read this article for free.

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Applied Therapeutics' rare disease drug gets a CRL

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Novartis to cut 139 jobs in NJ as part of commercial refocus

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Ex­clu­sive: Prison and multi­bil­lion dol­lar buy­outs lat­er, Sam Wak­sal is all in on the biotech game, with some big-name back­ers

Amber Tong

Sign up to read this article for free.

more like this

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Exclusive: Prison and multibillion dollar buyouts later, Sam Waksal is all in on the biotech game, with some big-name backers

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Applied Therapeutics' rare disease drug gets a CRL

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Novartis to cut 139 jobs in NJ as part of commercial refocus

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks